The Gornergrat Bahn beneath the Matterhorn at sunrise
Trampoline Venture Partners

Conviction capital,
deployed early.

A private investment office with global reach, backing exceptional founders directly, from pre-seed to Series B. Sector and country agnostic, with conviction in applied AI in longevity biotech, robotics, and fintech. Always searching for deep technology and frontier science. I look for founder quality, an unfair edge, and a reason it has to happen now.

By the numbers
40
Investments since 2021
19
Startups
11
Countries
$2.2bn
Combined portfolio company value
3.8x
Gross MOIC
Series B
Stage · up to

Early markers behind the numbers: one exit returned at 1.8x MOIC, one unicorn on the horizon, and one IPO in motion for 2026.

Selected outcomes

A few that shaped the thesis and proved the model.

Tim Guilliams, Healx
AI drug discovery for rare diseases.
Tim Guilliams, Co-founder & CEO. Cambridge PhD, Biophysics & Neuroscience. Dave Brown, Co-founder & CSO. Co-inventor on the Viagra patent at Pfizer.
Cambridge (UK)
Current Gross MOIC 4x
Marcelo Cavazzoli, Lemon
Your wallet in Latin America.
Marcelo Cavazzoli, Founder & CEO. University of Buenos Aires, Engineering.
Buenos Aires (Argentina)
Current Gross MOIC 50x
Dina Burkitbayeva, Freedom Bio
Next-generation combination therapies with ketamine and other neuropsychiatric therapeutics.
Dina Burkitbayeva, Co-founder & CEO. Harvard Business School, MBA. John Krystal, Co-founder & CSO. Yale, Chair of Psychiatry.
San Francisco, Yale (US)
Current Gross MOIC 5x
Selected portfolio

Builders, across continents.

Founder quality first. Valuation discipline. Asymmetric upside. Trust before transaction, and patience long after it.